Juno Biomedical, Inc. joins Singularity University’s Second Accelerator

Regenerative Medicine Startup Working to Solve One of Humanity’s Grand Challenges

Mountain View, Calif., May 5, 2016 — Juno Biomedical Inc., a medtech startup developing a revolutionary technology to repair damaged brain tissue in stroke victims, has been selected by Singularity University to participate in their SU Labs Startup Accelerator program. Acceptance into the program is limited to companies with potential to improve the quality of life of at least 1 billion people worldwide.

Juno Biomedical, Inc. is on a mission to improve quality of life for patients after neurological damage. With a technology, developed in part at UC Davis, that could change the standard of care for survivors of stroke and brain injury, Juno Biomedical will now be joining other pioneering ventures at Singularity University in Silicon Valley. Juno Biomedical CEO, Trisha Pfluger, will participate in Singularity’s 8-week intensive program designed to accelerate the company’s progress toward commercialization.

Singularity University’s Startup Accelerator is a highly selective program that carefully identifies startups using cutting-edge technologies to solve humanity’s grand challenges. Once selected by Singularity University, these companies gain access to a community of thought leaders, preeminent innovators and seed capital to progress their company at an accelerated pace.

“Singularity University’s program is perhaps the only accelerator where your homework is to better the lives of at least 1 billion people worldwide,” Trisha says, adding: “That’s why it’s known as the ‘university of the future’. We are honored to be one of only four companies participating in this program over the next two months.”

With more than 30 million stroke survivors worldwide and 800,000 new cases each year in the United States alone there is a substantial need for Juno Biomedical’s technology. Currently, there is no treatment that repairs brain tissue damage and stroke survivors must adapt to their disability. Ischemic stroke therapies and devices aim only to minimize further damage after stroke or to treat the symptoms of neurological damage, not reverse the underlying impairment. Juno Biomedical’s CELLTech™ technology is intended to heal brain tissue damage by facilitating new neural connections between functional cells and has been shown in pre-clinical trials to be safe and effective. This revolutionary technology could return stroke and brain injury patients who currently have no other options to a state of well-being.

About Juno Biomedical, Inc.
Juno Biomedical was launched in 2014 in Davis, CA by scientist and inventor Trisha Pfluger with an aim to improve the current standard of care for persons with neurological impairment. Founded on the idea that patient care should heal the underlying cause of disease rather than only alleviate the symptoms, Juno Biomedical endeavors to integrate exponential technologies such as digital patient monitoring, bioelectric therapy, and tissue regeneration to create an innovative medical device that can heal brain tissue damage. Now headquartered in Mountain View, CA, the company is pioneering advances not only in healing, but in personalized, in-home medical care. For further information, visit JunoBiomedical.com.


Leave a Reply